Baxalta reports positive phase 1 results for BAX 930
Baxalta has reported positive results from a Phase 1 open-label, dose escalation study assessing the safety and pharmacokinetic (PK) profile of BAX 930, an investigational recombinant ADAMTS13 for treatment of patients with severe hereditary thrombotic thrombocytopenic purpura. May 25, 2016